Literature DB >> 35511436

Activated CLL cells regulate IL-17F-producing Th17 cells in miR155-dependent and outcome-specific manners.

Byeongho Jung1,2, Gerardo Ferrer1, Pui Yan Chiu3, Rukhsana Aslam1,3, Anita Ng1, Florencia Palacios1, Michael Wysota2, Martina Cardillo1, Jonathan E Kolitz1,4,5, Steven L Allen1,4,5, Jacqueline C Barrientos1,4,5, Kanti R Rai1,4,5, Nicholas Chiorazzi1,4,5, Barbara Sherry3,4,5.   

Abstract

Chronic lymphocytic leukemia (CLL) results from expansion of a CD5+ B cell clone that requires interactions with other cell types, including T cells. Moreover, patients with CLL have elevated levels of circulating IL-17A+ and IL-17F+ CD4+ T (Th17) cells, with higher numbers of IL-17A+ Th17 cells correlating with better outcomes. We report that CLL Th17 cells expressed more miR155, a Th17-differentiation regulator, than control Th17 cells, despite naive CD4+ T (Tn) cell basal miR155 levels being similar in both. We also found that CLL cells directly regulated miR155 levels in Tn cells, thereby affecting Th17 differentiation, by documenting that coculturing Tn cells with resting or activated (Bact) CLL cells altered the magnitude and direction of T cell miR155 levels; CLL Bact cells promoted IL-17A+ and IL-17F+ T cell generation by an miR155-dependent mechanism, confirmed by miR155 inhibition; coculture of Tn cells with CLL Bact cells led to a linear correlation between the degree and direction of T cell miR155 expression changes and production of IL-17F but not IL-17A; and Bact cell-mediated changes in Tn cell miR155 expression correlated with outcome, irrespective of IGHV mutation status, a strong prognostic indicator. These results identify a potentially unrecognized CLL Bact cell-dependent mechanism, upregulation of Tn cell miR155 expression and subsequent enhancement of IL-17F+ Th17 generation, that favors better clinical courses.

Entities:  

Keywords:  Cytokines; Hematology; Immunology; Leukemias; T cells

Mesh:

Substances:

Year:  2022        PMID: 35511436      PMCID: PMC9309044          DOI: 10.1172/jci.insight.158243

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  68 in total

1.  T type 1/type 2 subsets balance in B-cell chronic lymphocytic leukemia--the three-color flow cytometry analysis.

Authors:  Monika Podhorecka; Anna Dmoszynska; Jacek Rolinski; Ewa Wasik
Journal:  Leuk Res       Date:  2002-07       Impact factor: 3.156

2.  Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia ("accelerated" chronic lymphocytic leukemia) with aggressive clinical behavior.

Authors:  Eva Giné; Antoni Martinez; Neus Villamor; Armando López-Guillermo; Mireia Camos; Daniel Martinez; Jordi Esteve; Xavier Calvo; Ana Muntañola; Pau Abrisqueta; Maria Rozman; Ciril Rozman; Francesc Bosch; Elias Campo; Emili Montserrat
Journal:  Haematologica       Date:  2010-04-26       Impact factor: 9.941

3.  AHR drives the development of gut ILC22 cells and postnatal lymphoid tissues via pathways dependent on and independent of Notch.

Authors:  Jacob S Lee; Marina Cella; Keely G McDonald; Cecilia Garlanda; Gregory D Kennedy; Manabu Nukaya; Alberto Mantovani; Raphael Kopan; Christopher A Bradfield; Rodney D Newberry; Marco Colonna
Journal:  Nat Immunol       Date:  2011-11-20       Impact factor: 25.606

4.  Proliferation centres in B-cell malignant lymphoma, lymphocytic (B-CLL): an immunophenotypic study.

Authors:  C Schmid; P G Isaacson
Journal:  Histopathology       Date:  1994-05       Impact factor: 5.087

5.  An IL-17F.S65L Knock-In Mouse Reveals Similarities and Differences in IL-17F Function in Oral Candidiasis: A New Tool to Understand IL-17F.

Authors:  Chunsheng Zhou; Leticia Monin; Rachael Gordon; Felix E Y Aggor; Rami Bechara; Tara N Edwards; Daniel H Kaplan; Sebastien Gingras; Sarah L Gaffen
Journal:  J Immunol       Date:  2020-06-29       Impact factor: 5.422

6.  The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia.

Authors:  Yair Herishanu; Patricia Pérez-Galán; Delong Liu; Angélique Biancotto; Stefania Pittaluga; Berengere Vire; Federica Gibellini; Ndegwa Njuguna; Elinor Lee; Lawrence Stennett; Nalini Raghavachari; Poching Liu; J Philip McCoy; Mark Raffeld; Maryalice Stetler-Stevenson; Constance Yuan; Richard Sherry; Diane C Arthur; Irina Maric; Therese White; Gerald E Marti; Peter Munson; Wyndham H Wilson; Adrian Wiestner
Journal:  Blood       Date:  2010-10-12       Impact factor: 22.113

7.  MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia.

Authors:  Bing Cui; Liguang Chen; Suping Zhang; Marek Mraz; Jessie-F Fecteau; Jian Yu; Emanuela M Ghia; Ling Zhang; Lei Bao; Laura Z Rassenti; Karen Messer; George A Calin; Carlo M Croce; Thomas J Kipps
Journal:  Blood       Date:  2014-06-09       Impact factor: 22.113

8.  T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production.

Authors:  John C Riches; Jeffrey K Davies; Fabienne McClanahan; Rewas Fatah; Sameena Iqbal; Samir Agrawal; Alan G Ramsay; John G Gribben
Journal:  Blood       Date:  2012-12-17       Impact factor: 22.113

9.  Leukemia-cell proliferation and disease progression in patients with early stage chronic lymphocytic leukemia.

Authors:  E J Murphy; D S Neuberg; L Z Rassenti; G Hayes; R Redd; C Emson; K Li; J R Brown; W G Wierda; S Turner; A W Greaves; C S Zent; J C Byrd; C McConnel; J Barrientos; N Kay; M K Hellerstein; N Chiorazzi; T J Kipps; K R Rai
Journal:  Leukemia       Date:  2017-01-24       Impact factor: 11.528

10.  AHR and the Transcriptional Regulation of Type-17/22 ILC.

Authors:  Jacob S Lee; Marina Cella; Marco Colonna
Journal:  Front Immunol       Date:  2012-02-06       Impact factor: 7.561

View more
  1 in total

Review 1.  Effects of ibrutinib on T-cell immunity in patients with chronic lymphocytic leukemia.

Authors:  Yanyan Liu; Yongping Song; Qingsong Yin
Journal:  Front Immunol       Date:  2022-08-19       Impact factor: 8.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.